GeneDx Holdings (WGS) Fundamental Analysis: Revenue, Earnings & Valuation

1.24 / 10

Underperform

Fundamental analysis rates WGS as Underperform, scoring only 1.24/10. Asset‑to‑market and profit metrics are poor, while current‑asset ratio and interest coverage are modestly positive. Overall, the company’s financial positioning is weak, suggesting limited upside.

Analysis Checks(7/10)

Profit-MV

Value0.68

Score1/3

Weight29.47%

1M Return-3.58%

Net income-Revenue

Value-0.04

Score1/3

Weight35.78%

1M Return-4.57%

Quick ratio

Value2.34

Score2/3

Weight0.06%

1M Return-0.01%

Rate of return on total assets (%)

Value-3.94

Score2/3

Weight5.26%

1M Return-0.49%

Fixed assets turnover ratio

Value6.53

Score2/3

Weight11.97%

1M Return-1.17%

Long-term debt to working capital ratio (%)

Value0.67

Score3/3

Weight-29.70%

1M Return2.80%

Annualized return on total assets (%)

Value-3.94

Score2/3

Weight5.26%

1M Return-0.49%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight18.82%

1M Return-1.91%

Asset-MV

Value-0.48

Score0/3

Weight-1.72%

1M Return0.21%

Current assets / Total assets (%)

Value51.23

Score2/3

Weight24.80%

1M Return-2.61%

Is WGS undervalued or overvalued?

WGS scores 1.24/10 on fundamentals and holds a Premium valuation at present. Backed by its -7.60% ROE, -4.92% net margin, -79.54 P/E ratio, 5.43 P/B ratio, and 62.37% earnings growth, these metrics solidify its Underperform investment rating.